(以下内容从开源证券《医药生物行业周报:体内CAR-T交易迭起,关注国内投资机会》研报附件原文摘录)近期全球达成多项体内CAR-T重磅交易,国内蕴藏较大机会体内CAR-T正凭借其独特优势成为细胞治疗领域新的热点方向,各大药企纷纷入场,2025年内交易频出。2025年3月,阿斯利康以10亿美元收购EsoBiotech;6月,艾伯维21亿美元买下Capstan Therapeutics;8月,...
Source Link(以下内容从开源证券《医药生物行业周报:体内CAR-T交易迭起,关注国内投资机会》研报附件原文摘录)近期全球达成多项体内CAR-T重磅交易,国内蕴藏较大机会体内CAR-T正凭借其独特优势成为细胞治疗领域新的热点方向,各大药企纷纷入场,2025年内交易频出。2025年3月,阿斯利康以10亿美元收购EsoBiotech;6月,艾伯维21亿美元买下Capstan Therapeutics;8月,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.